文献速递浆细胞疾病

伊沙佐米-沙利度胺-地塞米松全口服方案治疗复发/难治多发性骨髓瘤的II期试验

A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
PubMed 文献 · Br J Haematol · 2021-05-15

该II期试验评估了连续伊沙佐米-沙利度胺-地塞米松(ITd)方案治疗复发/难治多发性骨髓瘤(RRMM)的疗效与耐受性。

核心结论

  • ITd方案作为可负担的全口服PI-IMiD联合方案,在RRMM中显示出有前景的疗效和耐受性。

研究设计与样本

  • II期临床试验,纳入39例年龄≥18岁、既往接受1-3线治疗的复发/难治多发性骨髓瘤患者,来自澳大利亚维多利亚和南澳大利亚的两个三级中心。

主要发现

  • 既往蛋白酶体抑制剂和/或免疫调节剂暴露患者的生存结局相似。

关键数值与推荐

  • ITd方案:伊沙佐米4 mg,第1、8、15天;沙利度胺100 mg每日;地塞米松40 mg每周。
  • 患者接受中位11个周期(范围1-31)的治疗,最终分析时6例(15%)仍在治疗。

临床怎么用

  • ITd可作为复发/难治多发性骨髓瘤患者的一种全口服、可负担的治疗选择。
  • 对于既往免疫调节剂暴露的患者,应预期较低的缓解率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We evaluated the efficacy and tolerability of continuous ixazomib-thalidomide-dexamethasone (ITd: 4 mg, day 1, 8, 15; 100 mg daily; and 40 mg weekly). A total of 39 patients with relapsed/refractory multiple myeloma (RRMM) aged ≥18 years with one to three prior lines of therapy were enrolled from two tertiary centres in Victoria and South Australia, Australia. The overall response rate (ORR) was 56·4% with a clinical benefit rate of 71·8%. The median progression-free survival was 13·8 months [95% confidence interval (CI) 8·2-22·2] and median overall survival was not reached. The median time to best response and duration of response was 3·7 months (95% CI 2·8-10·5) and 18·4 months (95% CI 10·2-31·0) respectively. Prior immunomodulatory drug (IMID) exposure was associated with a lower ORR (40% vs. 73·7%, P = 0·03). Survival outcomes in patients with prior proteasome inhibitor (PI) and/or IMID exposure were similar. Patients received a median (range) of 11 (1-31) cycles of therapy and six patients (15%) remained on therapy at the time of final analysis. Grade 3/4 haematological and non-haematological adverse events were reported in 7·7% and 20·6% of patients respectively. ITd dose reductions were required in 15·4%, 48·7% and 35·9% of patients respectively. The present study demonstrates promising effectiveness and tolerability of ITd as an affordable all-oral PI-IMID approach for RRMM.

来源:Br J Haematol,查看原文。版权归原作者所有。

引用

  1. Bergin K, Yuen F, Wallington-Beddoe C, et al. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial. Br J Haematol. 2021. PMID: 33991421. doi:10.1111/bjh.17504

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。